- Home
- PAYS vs TOVX Comparison
PAYS vs TOVX Comparison
Compare PAYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- TOVX
- Stock Information
- Founded
- PAYS 1995
- TOVX 2001
- Country
- PAYS United States
- TOVX United States
- Employees
- PAYS 123
- TOVX N/A
- Industry
- PAYS Business Services
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- TOVX Health Care
- Exchange
- PAYS Nasdaq
- TOVX Nasdaq
- Market Cap
- PAYS 160.1M
- TOVX 3.5M
- IPO Year
- PAYS 1998
- TOVX 2006
- Fundamental
- Price
- PAYS $2.99
- TOVX $1.14
- Analyst Decision
- PAYS Strong Buy
- TOVX Strong Buy
- Analyst Count
- PAYS 3
- TOVX 1
- Target Price
- PAYS $6.17
- TOVX $6.00
- AVG Volume (30 Days)
- PAYS 169.3K
- TOVX 96.3K
- Earning Date
- PAYS 11-05-2024
- TOVX 11-12-2024
- Dividend Yield
- PAYS N/A
- TOVX N/A
- EPS Growth
- PAYS 368.11
- TOVX N/A
- EPS
- PAYS 0.14
- TOVX N/A
- Revenue
- PAYS $56,467,600.00
- TOVX N/A
- Revenue This Year
- PAYS $25.62
- TOVX N/A
- Revenue Next Year
- PAYS $13.23
- TOVX N/A
- P/E Ratio
- PAYS $21.59
- TOVX N/A
- Revenue Growth
- PAYS 27.75
- TOVX N/A
- 52 Week Low
- PAYS $2.40
- TOVX $1.14
- 52 Week High
- PAYS $5.59
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- PAYS 30.52
- TOVX 36.15
- Support Level
- PAYS $2.81
- TOVX $1.23
- Resistance Level
- PAYS $3.17
- TOVX $1.21
- Average True Range (ATR)
- PAYS 0.14
- TOVX 0.07
- MACD
- PAYS -0.02
- TOVX 0.01
- Stochastic Oscillator
- PAYS 21.33
- TOVX 0.00
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.